Status:
COMPLETED
Fluoropyrimidine Tailored-dose Based on Uracil Concentration in Patients Treated for Digestive Carcinomas: Evaluation of Clinical Practice
Lead Sponsor:
Hospices Civils de Lyon
Conditions:
Digestive Carcinoma
Eligibility:
All Genders
18+ years
Brief Summary
Digestive carcinomas chemotherapies regimen are mostly based on fluoropyrimidine drugs (5-Fluorouracil (5-FU) or capecitabine). 5-FU is mainly catabolised by dihydropyrimidine dehydrogenase (DPD) and ...
Eligibility Criteria
Inclusion
- Digestive cancer
- An uracil dosage performed between February 2018 to January 2020
- Received at least one cycle of fluoropyrimidine-based chemotherapy in one of the three oncology departments (Hopital Edouard Heriot \[Lyon\], Centre Hospitalier de Lyon Sud \[Lyon\], Hopital de la Croix Rousse \[Lyon\]).
Exclusion
- Age limit less than 18 years
- Not treated with fluoropyrimidine based chemotherapy
- Missing data for uracil concentration or chemotherapy dosage
Key Trial Info
Start Date :
November 2 2020
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
April 15 2021
Estimated Enrollment :
334 Patients enrolled
Trial Details
Trial ID
NCT04918264
Start Date
November 2 2020
End Date
April 15 2021
Last Update
June 8 2021
Active Locations (3)
Enter a location and click search to find clinical trials sorted by distance.
1
Hopital Edouard Heriot, Centre Hospitalier de Lyon Sud [Lyon], Hopital de la Croix Rousse [Lyon]
Lyon, France, 69003
2
Hopital de la Croix Rousse
Lyon, France, 69004
3
Centre Hospitalier de Lyon Sud
Pierre-Bénite, France, 69495